Cargando…
Microbial Identification Using DNA Target Amplification and Sequencing: Clinical Utility and Impact on Patient Management
Broad-range polymerase chain reaction (PCR) is increasingly used in patients with culture-negative infections; however, few studies have assessed the diagnostic utility of this test in this context. We performed a retrospective cohort study of patients who had clinical specimens sent for broad-range...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6284463/ https://www.ncbi.nlm.nih.gov/pubmed/30539032 http://dx.doi.org/10.1093/ofid/ofy257 |
_version_ | 1783379339338842112 |
---|---|
author | Basein, Tinzar Gardiner, Bradley J Andujar Vazquez, Gabriela M Joel Chandranesan, Andrew S Rabson, Arthur R Doron, Shira Snydman, David R |
author_facet | Basein, Tinzar Gardiner, Bradley J Andujar Vazquez, Gabriela M Joel Chandranesan, Andrew S Rabson, Arthur R Doron, Shira Snydman, David R |
author_sort | Basein, Tinzar |
collection | PubMed |
description | Broad-range polymerase chain reaction (PCR) is increasingly used in patients with culture-negative infections; however, few studies have assessed the diagnostic utility of this test in this context. We performed a retrospective cohort study of patients who had clinical specimens sent for broad-range PCR, aiming to evaluate performance and determine impact on patient management. Organisms were identified in 21/71 samples. High numbers of polymorphonuclear leukocytes on Gram stain (odds ratio [OR], 4.17; P = .04) and acute inflammation on histopathology (OR, 5.69; P = .02) were significantly associated with a positive result. Management was altered in 18 patients, 11 with positive and 7 with negative results. Overall, broad-range PCR assay had the highest impact in patients with microscopic evidence of inflammation. Physicians ordering this complex, difficult to interpret, and expensive test should carefully consider all available clinical information on an individualized basis to optimize its performance. |
format | Online Article Text |
id | pubmed-6284463 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-62844632018-12-11 Microbial Identification Using DNA Target Amplification and Sequencing: Clinical Utility and Impact on Patient Management Basein, Tinzar Gardiner, Bradley J Andujar Vazquez, Gabriela M Joel Chandranesan, Andrew S Rabson, Arthur R Doron, Shira Snydman, David R Open Forum Infect Dis Major Article Broad-range polymerase chain reaction (PCR) is increasingly used in patients with culture-negative infections; however, few studies have assessed the diagnostic utility of this test in this context. We performed a retrospective cohort study of patients who had clinical specimens sent for broad-range PCR, aiming to evaluate performance and determine impact on patient management. Organisms were identified in 21/71 samples. High numbers of polymorphonuclear leukocytes on Gram stain (odds ratio [OR], 4.17; P = .04) and acute inflammation on histopathology (OR, 5.69; P = .02) were significantly associated with a positive result. Management was altered in 18 patients, 11 with positive and 7 with negative results. Overall, broad-range PCR assay had the highest impact in patients with microscopic evidence of inflammation. Physicians ordering this complex, difficult to interpret, and expensive test should carefully consider all available clinical information on an individualized basis to optimize its performance. Oxford University Press 2018-10-10 /pmc/articles/PMC6284463/ /pubmed/30539032 http://dx.doi.org/10.1093/ofid/ofy257 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Major Article Basein, Tinzar Gardiner, Bradley J Andujar Vazquez, Gabriela M Joel Chandranesan, Andrew S Rabson, Arthur R Doron, Shira Snydman, David R Microbial Identification Using DNA Target Amplification and Sequencing: Clinical Utility and Impact on Patient Management |
title | Microbial Identification Using DNA Target Amplification and Sequencing: Clinical Utility and Impact on Patient Management |
title_full | Microbial Identification Using DNA Target Amplification and Sequencing: Clinical Utility and Impact on Patient Management |
title_fullStr | Microbial Identification Using DNA Target Amplification and Sequencing: Clinical Utility and Impact on Patient Management |
title_full_unstemmed | Microbial Identification Using DNA Target Amplification and Sequencing: Clinical Utility and Impact on Patient Management |
title_short | Microbial Identification Using DNA Target Amplification and Sequencing: Clinical Utility and Impact on Patient Management |
title_sort | microbial identification using dna target amplification and sequencing: clinical utility and impact on patient management |
topic | Major Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6284463/ https://www.ncbi.nlm.nih.gov/pubmed/30539032 http://dx.doi.org/10.1093/ofid/ofy257 |
work_keys_str_mv | AT baseintinzar microbialidentificationusingdnatargetamplificationandsequencingclinicalutilityandimpactonpatientmanagement AT gardinerbradleyj microbialidentificationusingdnatargetamplificationandsequencingclinicalutilityandimpactonpatientmanagement AT andujarvazquezgabrielam microbialidentificationusingdnatargetamplificationandsequencingclinicalutilityandimpactonpatientmanagement AT joelchandranesanandrews microbialidentificationusingdnatargetamplificationandsequencingclinicalutilityandimpactonpatientmanagement AT rabsonarthurr microbialidentificationusingdnatargetamplificationandsequencingclinicalutilityandimpactonpatientmanagement AT doronshira microbialidentificationusingdnatargetamplificationandsequencingclinicalutilityandimpactonpatientmanagement AT snydmandavidr microbialidentificationusingdnatargetamplificationandsequencingclinicalutilityandimpactonpatientmanagement |